No

Vaccine, Live Virus

Adults born before 1957 are generally considered to be immune. All those born in or after 1957 without documentation of live vaccine on or after first birthday, physician-diagnosed measles, or laboratory evidence of immunity should be vaccinated, ideally with two doses of vaccine separated by no less than 1 month. For those previously vaccinated with one dose of measles vaccine, revaccination is recommended for students entering colleges and other institutions of higher education, for healthcare workers at the time of employment, and for international travelers who visit endemic areas.

X

Pregnant females, known anaphylactoid reaction to eggs, known hypersensitivity to neomycin, acute respiratory infections, activated tuberculosis, immunosuppressed patients

Avoid use in immunocompromised patients; defer administration in presence of acute respiratory or other active infections or inactive, untreated tuberculosis; avoid pregnancy for 3 months following vaccination; history of febrile seizures, hypersensitivity reactions may occur

All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Cardiovascular: Edema

Central nervous system: Fever (<100°F)

Local: Burning or stinging, induration

1% to 10%:

Central nervous system: Fever between 100°F and 103°F usually between 5th and 12th days postvaccination

Dermatologic: Rash (rarely generalized)

<1%: Fatigue, convulsions, encephalitis, confusion, severe headache, fever (>103°F - prolonged), palsies, Guillain-Barré syndrome, ataxia, urticaria, itching, reddening of skin (especially around ears and eyes), erythema multiforme, vomiting, sore throat, diarrhea, thrombocytopenic purpura, diplopia, stiff neck, dyspnea, cough, rhinitis, lymphadenopathy, coryza, allergic reactions

Whole blood, interferon immune globulin, radiation therapy, and immunosuppressive drugs (eg, corticosteroids) may result in insufficient response to immunization. DTP, OPV, MMR, Hib, and hepatitis B may be given concurrently; other virus vaccine administration should be separated by greater than or equal to 1 month from measles.

Refrigerate at 2°C to 8°C (36°F to 46°F); discard if left at room temperature for over 8 hours; protect from light

Promotes active immunity to measles virus by inducing specific measles IgG and IgM antibodies.

Children greater than or equal to 15 months and Adults: S.C.: 0.5 mL in outer aspect of the upper arm, no routine boosters

Vaccine should not be given I.V.; S.C. injection preferred

May temporarily depress tuberculin skin test sensitivity

No information available to require special precautions

No effects or complications reported

Parents should monitor children closely for fever for 5-11 days after vaccination; females should not become pregnant within 3 months of vaccination

Vaccine should not be administered I.V.; S.C. injection preferred with a 25-gauge 5/8 " needle; federal law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title and address be entered into the patient's permanent medical record

Injection: 1000 TCID₅₀ per dose

Gardner P and Schaffner W, "Immunization of Adults," N Engl J Med, 1993, 328(17):1252-8.